≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Drug-induced gout

Endpoint Browser PheWeb

DRUGADVERS_GOUT

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M10.2#

1 out of 7 registries used, show all original rules.

182

4. Check minimum number of events

None

182

5. Include endpoints

None

182

6. Filter based on genotype QC (FinnGen only)

160

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2039 925 1082
Only index persons 1283 594 689
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.03
Only index persons 0.02 0.02 0.03
Median age at first event (years)
Whole population 75.80 79.20 72.91
Only index persons 74.55 78.74 70.93

-FinnGen-

Key figures

All Female Male
Number of individuals 160 50 110
Unadjusted period prevalence (%) 0.04 0.02 0.05
Median age at first event (years) 70.69 74.77 68.84

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
162
Matched controls
1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M10.2
ICD-10 Finland
Drug-induced gout
+∞
232.1
162
*
M04AA01
ATC
allopurinol; systemic
65.4
120.7
147
211
M10.9
ICD-10 Finland
Gout, unspecified
17.8
75.0
80
84
M10.0
ICD-10 Finland
Idiopathic gout
15.2
39.1
38
32
212
Kela drug reimbursment
Gout
13.9
30.0
30
26
C03CA01
ATC
furosemide; systemic
8.4
28.0
136
621
I50.9
ICD-10 Finland
Heart failure, unspecified
5.7
27.7
94
314
B01AA03
ATC
warfarin; systemic
5.6
26.5
99
356
I50.0
ICD-10 Finland
Congestive heart failure
6.1
26.2
62
150
I50.1
ICD-10 Finland
Left ventricular failure
7.4
24.7
42
73
C03DA01
ATC
spironolactone; oral
5.2
21.1
59
162
C01AA05
ATC
digoxin; systemic
4.9
18.5
53
147
A46
ICD-10 Finland
Erysipelas
4.3
17.3
62
203
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.4
16.8
39
90
M10
ICD-10 Finland
Gout
6.6
15.7
28
50
M13.9
ICD-10 Finland
Arthritis, unspecified
5.8
15.2
31
63
N17.9
ICD-10 Finland
Acute renal failure, unspecified
6.2
14.8
28
53
I48
ICD-10 Finland
Atrial fibrillation and flutter
3.6
14.6
90
418
205
Kela drug reimbursment
Chronic hypertension
3.6
14.3
96
469
R06.0
ICD-10 Finland
Dyspnoea
3.4
13.3
79
354
C03EB01
ATC
furosemide and potassium-sparing agents; systemic
5.5
13.2
28
59
C03AA03
ATC
hydrochlorothiazide; oral
4.4
13.0
38
105
201
Kela drug reimbursment
Chronic cardiac insufficiency
4.4
12.6
37
102
C07AB07
ATC
bisoprolol; oral
3.9
12.5
126
768
C09AA02
ATC
enalapril; systemic
3.3
12.4
71
308
H02AB06
ATC
prednisolone; systemic
3.4
12.2
110
622
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
5.8
11.1
22
43
I11.0
ICD-10 Finland
Hypertensive heart disease with (congestive) heart failure
5.5
10.1
21
43
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.8
9.4
77
396
E66.00
ICD-10 Finland
Metabolic syndrome
5.5
9.3
19
38
C01DA14
ATC
isosorbide mononitrate; oral
2.8
9.1
68
332
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.2
9.1
20
43
I25.2
ICD-10 Finland
Old myocardial infarction
3.5
9.0
35
117
I50
ICD-10 Finland
Heart failure
4.9
8.6
20
45
C09BA02
ATC
enalapril and diuretics; systemic
3.5
8.5
34
115
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.9
8.4
27
79
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.6
8.4
82
455
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.5
8.1
21
52
R60.0
ICD-10 Finland
Localized oedema
3.1
7.8
38
145
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
8.3
7.6
16
21
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
7.5
49
220
288
Kela drug reimbursment
Febuxostat
83.8
7.5
8
*
M04AA03
ATC
febuxostat; oral
83.8
7.5
8
*
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
2.7
7.1
46
205
C07AG02
ATC
carvedilol; oral
3.6
7.0
25
78
R03BB04
ATC
tiotropium bromide; inhalant
2.9
7.0
39
160
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.9
7.0
38
154
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.8
6.9
40
168
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
4.1
6.9
20
54
207
Kela drug reimbursment
Chronic arrhythmias
2.6
6.8
53
258
M01AB01
ATC
indometacin; systemic, rectal
3.3
6.8
28
96
81
HP
Angiography of the heart and coronary arteries
3.2
6.8
29
102
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.7
6.8
42
183
103
Kela drug reimbursment
Diabetes, insulin-treated
2.4
6.7
73
414
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.7
6.7
42
184
J96.1
ICD-10 Finland
Chronic respiratory failure
8.0
6.6
14
19
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
4.4
6.5
17
42
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
6.5
61
323
N18.8
ICD-10 Finland
Other chronic renal failure
6.5
6.5
16
27
C02EA02, ,
ATC
3.6
6.4
23
72
C02AC05
ATC
moxonidine; oral
4.1
6.3
18
48
E66.9
ICD-10 Finland
Obesity, unspecified
8.2
6.3
13
17
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.3
6.2
66
368
A11CC03
ATC
alfacalcidol; systemic
6.9
6.0
14
22

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
96
350
5.28
24.85
6.6
3.2
399.27
369.49
umol/l
1.40
86
288
41
176
2.78
6.78
1.4
1.3
73.83
43.05
iu/ml
0.34
20
56
38
158
2.84
6.66
1.4
1.4
13.96
24.69
u/ml
0.30
18
60
32
130
2.82
5.82
13.0
9.1
—
—
—
0
0
74
482
1.99
4.35
6.8
4.6
—
—
—
0
0
14
43
3.47
4.01
1.5
1.3
33717.78
5740.21
e6/l
—
9
28
33
163
2.29
3.96
6.9
3.9
7.35
7.38
ph
0.94
20
107
67
435
1.92
3.88
4.7
2.4
59.89
76.57
u/l
0.57
61
399
35
182
2.18
3.70
10.7
7.4
89.89
94.69
%
1.00
35
177
15
51
3.14
3.68
2.1
3.4
537.29
173.21
mg/l
—
7
19
41
228
2.07
3.65
2.2
2.0
—
—
—
0
0
38
207
2.09
3.57
10.4
6.7
5.31
5.04
kpa
0.68
38
198
38
207
2.09
3.57
10.3
6.7
8.87
11.26
kpa
4.88
38
199
58
369
1.89
3.51
5.6
2.9
3.94
4.06
e6/l
0.03
53
332
29
143
2.25
3.48
1.3
1.3
993.33
560.00
titre
—
6
38
37
205
2.04
3.31
10.5
7.0
7.39
7.41
ph
0.59
21
127
6
7
8.84
3.29
1.2
1.0
—
—
—
0
0
25
120
2.28
3.19
7.0
3.7
—
—
—
0
0
31
163
2.12
3.18
2.3
1.8
—
—
—
0
0
10
25
4.19
3.14
1.2
1.3
—
—
—
0
0
36
203
1.99
3.06
10.8
7.0
1.30
1.05
mmol/l
0.10
30
165
8
17
4.89
2.96
1.4
1.4
—
—
—
0
0
93
713
1.71
2.84
7.1
6.7
13.12
12.67
umol/l
0.16
86
674
41
249
1.87
2.80
12.0
6.7
103.68
104.00
mmol/l
0.14
41
249
19
88
2.31
2.63
6.6
2.9
1.48
1.17
%
0.81
19
88
7
15
4.82
2.62
1.0
1.4
21.90
42.17
ng/l
—
7
15
9
25
3.75
2.62
1.8
1.4
—
—
—
0
0
80
598
1.67
2.61
3.7
3.2
—
—
estimate
—
0
0
23
116
2.15
2.61
11.7
6.0
24.69
24.19
mmol/l
0.17
23
111
50
330
1.75
2.58
6.7
3.4
512.13
549.99
mosm/kgh2o
0.97
44
284
97
764
1.67
2.58
41.1
17.6
1.65
1.37
inr
3.60
87
651
10
31
3.37
2.56
1.1
1.6
0.29
0.25
g/l
—
10
31
10
31
3.37
2.56
1.1
1.7
1.41
1.14
g/l
—
10
31
30
171
1.93
2.46
1.5
1.2
—
—
—
0
0
60
427
1.64
2.31
7.0
3.7
0.64
0.40
e6/l
0.55
55
327
8
23
3.60
2.30
1.4
1.2
—
—
—
0
0
6
13
4.75
2.29
2.8
1.5
1023.17
988.62
mg
—
6
13
7
18
4.01
2.28
1.0
1.1
—
—
—
0
0
11
41
2.80
2.25
1.3
1.2
—
—
—
0
0
71
536
1.58
2.11
7.8
4.6
45.13
161.87
e6/l
1.98
61
410
68
510
1.57
2.07
7.0
3.8
13.73
206.38
e6/l
0.91
61
403
17
86
2.09
1.93
7.2
2.8
0.83
0.64
%
0.70
17
86
8
28
2.95
1.89
1.8
1.7
25.00
29.59
umol/l
—
8
22
60
446
1.55
1.87
4.3
2.9
—
—
—
0
0
6
17
3.62
1.85
1.3
1.3
—
—
—
0
0
83
665
1.51
1.81
6.6
4.8
51.81
0.00
estimate
0.49
26
158
6
18
3.42
1.76
2.3
1.6
4.59
5.04
e9/l
—
6
18
6
19
3.24
1.67
3.7
1.8
86.18
89.45
%
—
6
19
7
25
2.88
1.67
2.1
1.8
60.00
57.28
%
—
7
25
7
25
2.88
1.67
4.0
2.6
—
—
—
0
0
5
14
3.65
1.62
1.2
1.2
—
—
—
0
0
5
14
3.65
1.62
1.0
1.1
—
—
—
0
0
18
100
1.90
1.61
3.4
1.6
—
—
—
0
0
7
26
2.77
1.60
1.9
1.4
—
—
—
0
0
7
26
2.77
1.60
1.9
1.4
—
—
—
0
0
7
26
2.77
1.60
1.9
1.4
—
—
—
0
0
7
26
2.77
1.60
4.9
3.8
10.40
10.50
pmol/l
—
7
26
7
26
2.77
1.60
1.9
1.4
—
—
—
0
0
51
379
1.50
1.55
8.9
6.5
—
—
—
0
0
14
72
2.03
1.54
1.9
2.7
—
—
—
0
0
80
657
1.43
1.44
6.7
4.8
0.00
0.00
estimate
-0.00
25
152
39
279
1.52
1.41
1.8
1.6
1.14
1.68
mg/l
1.27
32
221
81
672
1.41
1.35
6.8
4.8
0.00
0.00
estimate
-0.00
22
143
28
395
0.65
1.27
3.5
3.5
0.91
0.89
ug/l
0.03
21
271
8
36
2.28
1.26
1.0
1.3
—
—
—
0
0
6
26
2.36
1.20
1.2
1.1
—
—
—
0
0
56
445
1.39
1.17
9.1
5.5
—
—
—
0
0
75
626
1.37
1.16
7.1
5.0
43.28
51.85
ng/l
0.45
61
511
7
30
2.39
1.14
1.3
1.4
—
—
—
0
0
19
121
1.65
1.11
3.4
2.1
—
—
—
0
0
39
294
1.43
1.09
6.7
5.3
1.02
1.02
kg/l
0.07
31
211
63
518
1.35
1.05
5.1
4.3
6.30
6.24
ph
0.17
40
295
60
491
1.35
1.03
6.3
4.3
47.21
9.95
mg/mmol
1.67
49
322
83
714
1.33
1.02
11.3
9.7
5.63
4.38
e9/l
2.05
78
619
77
658
1.32
0.98
11.5
6.1
1.67
1.75
e9/l
0.35
72
585
57
470
1.33
0.92
5.3
3.5
7.15
7.47
mmol/l
0.27
52
381
18
120
1.56
0.90
2.9
1.4
—
—
—
0
0
17
112
1.58
0.89
2.8
2.2
0.00
0.00
estimate
—
5
23
20
138
1.51
0.86
1.3
1.3
—
—
—
0
0
32
245
1.38
0.82
6.8
6.3
—
—
—
0
0
13
82
1.64
0.81
2.6
3.0
—
—
—
0
0
0
24
0.00
0.80
0.0
1.3
—
20.35
—
0
17
0
26
0.00
0.79
0.0
1.5
—
—
—
0
0
17
117
1.51
0.75
6.2
4.8
0.50
0.86
%
—
8
50
5
24
2.12
0.75
1.2
1.5
—
—
—
0
0
7
38
1.88
0.74
9.9
3.2
—
—
—
0
0
56
473
1.28
0.74
5.0
3.4
234.05
64.89
mg/l
1.25
49
323
101
1099
0.78
0.74
6.1
5.9
6.55
6.20
mmol/l
1.41
95
979
5
25
2.03
0.73
1.4
4.0
1.40
0.88
%
—
5
25
97
1058
0.79
0.71
5.8
5.5
1.18
1.40
mmol/l
6.48
89
947
74
651
1.25
0.69
10.5
6.0
0.68
0.63
e9/l
1.11
69
554
18
128
1.46
0.69
4.6
1.5
—
—
—
0
0
102
1104
0.79
0.68
6.8
6.5
2.04
2.41
mmol/l
5.84
94
993
26
199
1.37
0.68
1.6
1.4
3.14
3.13
g/l
0.01
17
108
74
653
1.25
0.67
10.6
6.0
0.04
0.04
e9/l
0.13
69
558
59
675
0.80
0.65
5.2
6.2
3.62
3.18
ug/l
0.14
53
597
59
510
1.25
0.64
7.2
5.0
0.09
0.04
estimate
0.22
23
131
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
22
0.00
0.60
0.0
1.2
—
1.73
—
0
15
47
400
1.25
0.58
7.5
4.8
0.00
0.02
estimate
0.50
21
132
41
482
0.80
0.56
2.6
2.3
—
—
—
0
0
99
1065
0.82
0.56
5.8
5.6
3.81
4.26
mmol/l
4.81
90
962
27
334
0.77
0.56
3.3
4.0
—
—
—
0
0
6
38
1.60
0.55
1.3
1.1
—
—
—
0
0
6
39
1.56
0.53
1.2
1.2
—
—
—
0
0
95
1023
0.83
0.53
4.8
4.7
1.60
1.24
mmol/l
4.03
85
910
15
109
1.41
0.53
6.9
4.9
0.00
0.10
%
—
7
42
6
40
1.52
0.52
28.0
15.2
—
—
—
0
0
13
94
1.42
0.47
2.5
1.5
—
—
—
0
0
15
112
1.37
0.46
6.0
4.7
0.17
0.39
%
—
6
47
30
249
1.25
0.46
5.2
3.6
2.00
1.76
e6/l
0.09
21
145
98
1045
0.84
0.45
5.2
5.0
2.39
2.07
mu/l
0.70
91
914
104
976
1.18
0.43
12.3
8.4
87.83
81.25
u/l
0.96
99
909
109
1150
0.84
0.43
37.6
19.6
—
—
—
0
0
112
1177
0.84
0.41
18.7
13.4
23.61
23.81
u/l
0.06
107
1136
61
550
1.17
0.41
24.2
13.8
0.00
0.01
e9/l
0.19
54
453
79
728
1.17
0.40
15.6
7.1
1.20
1.20
mmol/l
0.27
70
624
18
143
1.29
0.39
3.8
3.2
0.11
0.88
e6/l
0.68
18
137
13
168
0.75
0.38
1.4
1.4
—
—
—
0
0
53
477
1.17
0.36
4.8
3.7
—
—
—
0
0
10
73
1.39
0.35
2.7
3.2
—
—
—
0
0
49
441
1.16
0.33
12.2
4.1
7.39
7.39
ph
0.01
38
315
15
119
1.29
0.33
7.2
5.1
0.00
0.24
%
—
6
45
6
47
1.29
0.32
2.5
1.5
—
—
—
0
0
103
1079
0.88
0.31
10.0
7.9
43.31
41.26
mmol/mol
1.03
96
987
58
628
0.88
0.29
2.6
2.3
85.04
92.90
pmol/l
1.00
38
348
112
1163
0.88
0.27
46.1
21.6
25.96
27.61
mg/l
0.33
107
1027
5
73
0.68
0.26
1.0
1.2
—
—
—
0
0
10
78
1.30
0.25
2.3
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.5
—
—
—
0
0
13
108
1.22
0.21
1.3
1.4
—
—
—
0
0
87
908
0.91
0.20
52.3
27.6
15.21
14.12
%
5.16
87
898
19
165
1.17
0.20
2.5
1.4
—
—
—
0
0
7
58
1.22
0.18
3.4
5.5
—
—
—
0
0
5
46
1.09
0.09
1.4
1.2
—
—
—
0
0
5
60
0.83
0.08
1.0
1.2
—
—
—
0
0
12
108
1.12
0.07
5.5
2.7
5.71
6.19
ph
1.69
12
79
36
376
0.95
0.07
7.1
4.2
0.14
0.02
estimate
0.41
21
124
83
843
0.97
0.04
4.1
3.8
14.90
15.13
pmol/l
0.34
75
728
44
452
0.96
0.04
2.4
1.8
24.34
20.79
nmol/l
0.15
39
365
11
103
1.07
0.02
12.2
4.0
—
—
—
0
0
22
227
0.96
0.01
1.1
1.2
0.61
1.18
u/ml
—
7
61
15
146
1.03
0.00
3.4
3.2
4.62
5.90
e9/l
0.32
15
119
30
302
0.99
0.00
1.2
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
19.60
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
30.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
184.76
—
0
5
0
5
0.00
0.00
0.0
1.0
—
1.97
—
0
5
0
5
0.00
0.00
0.0
1.0
—
292.80
—
0
5
6
61
0.98
-0.00
1.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
3.51
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
1.06
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint DRUGADVERS_GOUT and mortality.

Females

Parameter HR [95% CI] p-value
DRUGADVERS_GOUT 2.636 [2.17, 3.21] < 0.001
Birth year 0.993 [0.98, 1.0] 0.103

During the follow-up period (1.1.1998 — 31.12.2019), 583 out of 777 females with DRUGADVERS_GOUT died.

Males

Parameter HR [95% CI] p-value
DRUGADVERS_GOUT 2.856 [2.31, 3.53] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 683 out of 935 males with DRUGADVERS_GOUT died.

Mortality risk

Mortality risk for people of age

years, who have DRUGADVERS_GOUT.

N-year risk Females Males
1 0.264% 0.645%
5 1.546% 3.143%
10 3.113% 7.409%
15 6.06% 14.055%
20 11.075% 22.563%

Relationships between endpoints

↥

Index endpoint: DRUGADVERS_GOUT – Drug-induced gout

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data